Methylphenidate

Centrally acting psychostimulant

ATC code: N06BA04 (Methylphenidate)

Mechanism of action

A presynaptic noradrenaline and dopamine reuptake inhibitor. Raises catecholamine concentration in prefrontal cortex synapses, improving attention, focus, and impulse control in ADHD patients. Structurally differs from amphetamines by less neurotransmitter release induction – lower abuse potential but still a controlled substance. Half-life 2–3 hours immediate-release; 8–12 hours OROS form (Concerta). In Spain prescribed only by specialists (psychiatrist or pediatrician).

Indications

ADHD

First line

First-line for attention-deficit hyperactivity disorder in children over 6 and adults per 2019, NG87 (2018), and the Spanish SEPyP 2024 consensus. Children start at 5 mg 1–2 times daily; adults at 18 mg (Concerta) once daily in the morning. Cortese 2018 meta-analysis showed efficacy 0.78 SMD on ADHD symptoms in children. Mandatory pre-treatment psychiatric assessment, cardiovascular risk evaluation (ECG, BP, arrhythmia family history), and baseline growth and weight. Reassessment every 3–6 months.

Sources

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Memory and concentration enhancement

Not recommended

Methylphenidate is a psychostimulant prescribed for attention-deficit/hyperactivity disorder (ADHD) in children over 6 and adults, and for narcolepsy ( 2019 and AAFP 2020 guidelines). Healthy students, programmers, and knowledge workers often take methylphenidate as a cognitive stimulant. The Repantis 2010 meta-analysis showed only a minimal effect on working memory and attention in healthy adults, far less than in genuine ADHD. Methylphenidate is a Schedule II controlled substance in the US because of high abuse potential. Use carries risks of hypertension, tachycardia, insomnia, appetite loss, anxiety, psychosis at high doses, and dependence. If methylphenidate is being taken for work concentration outside an ADHD indication, consider seeking a second opinion.

Sources

Practical notes

Common myths

Myth: «methylphenidate is a safe cognitive enhancer for students and knowledge workers without ADHD.» Fact: in healthy people without ADHD, methylphenidate does not improve learning or memory (Repantis 2010 meta-analysis) but raises the risk of dependence (especially with snorting or injection), cardiovascular events, and psychotic episodes. In Spain, the US, and the UK, unauthorized «for studying» use is a serious risk; it spreads via prescription-free channels where the drug is often counterfeit. Myth: «methylphenidate in children causes adult addiction.» Fact: the Wilens 2003 meta-analysis showed adequate ADHD therapy with methylphenidate lowers adult substance abuse risk, not raises. Untreated ADHD is itself a dependence risk factor.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMA

Spanish Medicines Information Centre (CIMA)

Label dated: 06/01/2026

FDA / DailyMed

FDA — DailyMed Drug Labels

Label dated: 10/07/2025

Safety

Boxed warning

FDA boxed warning: high abuse and dependence potential. Schedule II controlled substance (US), narcotic list in Spain. Not prescribed to patients with history of stimulant abuse or family history of dependence.

Contraindications

Methylphenidate hypersensitivity
Severe hypertension, hyperthyroidism, pheochromocytoma
Cardiovascular disease (angina, arrhythmias, cardiomyopathy, congenital heart defects)
Glaucoma
Psychotic disorders, severe depression, bipolar disorder (manic switch risk)
Anorexia or bulimia
Tics, Tourette syndrome
Age under 6
Concurrent MAO inhibitors or within 14 days of stopping
Pregnancy and lactation

Serious adverse effects

Cardiovascular events (sudden cardiac death, MI, stroke)
Psychotic episodes and hallucinations
Manic episodes in undiagnosed bipolar disorder
Tics (new or worsening)
Serotonin syndrome with SSRIs
Growth retardation in children with long-term use
Priapism (rare)

Common adverse effects

Reduced appetite and weight loss
Insomnia
Headache
Anxiety and irritability
Tachycardia and BP elevation

Frequently asked

What is Methylphenidate used for?

Methylphenidate is evaluated for the following indications with varying evidence strength: ADHD (evidence tier A), Memory and concentration enhancement (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Methylphenidate?

Common side effects of Methylphenidate (≥ 1 in 100): Reduced appetite and weight loss, Insomnia, Headache, Anxiety and irritability, Tachycardia and BP elevation, Dry mouth. See the Safety section for uncommon and serious reactions.

Is Methylphenidate safe during pregnancy?

FDA category C. Methylphenidate crosses the placenta. T1 use linked to a small increase in cardiac defect risk. T3 – neonatal withdrawal risk. Pregnancy use not recommended without clear indication.

Is Methylphenidate compatible with breastfeeding?

Milk concentrations are low, but infant insomnia and reduced weight gain are described. Use during lactation cautiously with monitoring of infant sleep and weight gain.

Who should not take Methylphenidate?

Methylphenidate is contraindicated in: Methylphenidate hypersensitivity; Severe hypertension, hyperthyroidism, pheochromocytoma; Cardiovascular disease (angina, arrhythmias, cardiomyopathy, congenital heart defects); Glaucoma; Psychotic disorders, severe depression, bipolar disorder (manic switch risk). Full list in the Safety section.